Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. for allegedly misleading investors regarding the company's sales growth and the factors driving it during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired BellRing securities from November 19, 2024, to August 4, 2025 [1][2]. - Investors have until March 23, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against BellRing - The complaint alleges that BellRing, along with its CEO and CFO, misrepresented sales growth as being driven by increased consumer demand and organic growth, while downplaying competitive impacts [3][4]. - Contrary to these claims, the lawsuit asserts that sales were primarily driven by inventory stockpiling by key customers [4]. Group 3: Impact on Stock Price - On May 6, 2025, following revelations about reduced inventory levels at key retailers, BellRing's stock price fell by $14.88, or 19%, from $78.43 to $63.55 per share [5]. - On August 4, 2025, after adjusting its fiscal year 2025 sales outlook due to competition, the stock plummeted by $17.46, or 33%, from $53.64 to $36.18 per share [6].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for allegedly misleading investors about the company's loan delinquencies during a specific period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Sallie Mae securities from July 25, 2025, to August 14, 2025 [1][2]. - Investors have until February 17, 2026, to seek appointment as lead plaintiff representative of the class [2]. - The complaint alleges that Sallie Mae misrepresented the rise in early-stage delinquencies, claiming these trends were typical and praising their loss mitigation strategies [3]. Group 2: Financial Impact - Following the revelation of the true state of loan delinquencies, Sallie Mae's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4].

Core Viewpoint - REGENXBIO Inc. is under investigation for potential violations of federal securities laws following the FDA's clinical holds on its RGX-111 and RGX-121 programs, which resulted in a significant decline in the company's share price by 30-35% [1]. Regulatory Compliance - SEC disclosure rules mandate that public companies must provide material information for informed investment decisions, with Form 8-K allowing disclosure of material events not covered by other items [2]. - Rule 10b-5 prohibits material misstatements and omissions in securities transactions, covering both false statements and the omission of necessary facts [2]. Earnings Call Insights - During the Q3 2025 earnings call, CEO Curran Simpson highlighted positive regulatory interactions, noting that the FDA completed inspections with no observations, which may have created an asymmetric presentation of the company's regulatory standing [3]. - The Q3 2025 earnings call did not address the RGX-111 program for MPS I, despite it being a material pipeline asset later subjected to the FDA clinical hold, raising concerns about the completeness of information provided to shareholders [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Klarna Group plc, alleging misrepresentations in the registration statement related to its September 2025 IPO, particularly concerning the company's business risks and loss reserves [1][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants materially understated the risk of increased loss reserves shortly after the IPO, which they either knew or should have known due to the risk profile of individuals using Klarna's buy now, pay later loans [3]. - Investors who purchased Klarna securities during the IPO are encouraged to join the class action lawsuit to discuss their legal rights and options [2]. Group 2: Legal Process - Individuals wishing to serve as lead plaintiff must file necessary documents by February 20, 2026, although participation as a lead plaintiff is not required to share in any potential recovery [4]. - All legal representation in this case is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4]. Group 3: Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Bath & Body Works, Inc. for alleged misrepresentations regarding the Company's financial guidance during the period from June 4, 2024, to November 19, 2025 [1][2]. Group 1 - The lawsuit is on behalf of investors who purchased or acquired Bath & Body Works securities within the specified timeframe [1]. - Investors interested in participating as lead plaintiffs must file necessary documents by March 13, 2026 [2]. - The law firm representing the class operates on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [4].

Core Viewpoint - Purcell & Lefkowitz LLP is investigating RingCentral, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions [1] Group 1 - The investigation is on behalf of RingCentral's shareholders [1] - Shareholders interested in more information about their rights and options can contact the law firm [1] Group 2 - Purcell & Lefkowitz LLP specializes in representing shareholders affected by securities fraud and corporate misconduct [2] - The firm emphasizes that prior results do not guarantee similar outcomes [2]

Core Viewpoint - Klarna Group plc is facing a class action lawsuit related to its September 10, 2025 IPO, alleging violations of the Securities Act of 1933 due to misleading offering documents and understated risk regarding loan loss reserves [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Nayak v. Klarna Group plc, allows purchasers of Klarna securities from the IPO to seek appointment as lead plaintiff by February 20, 2026 [1][2]. - Klarna's IPO involved the issuance of approximately 34 million shares at an offering price of $40.00 per share [2]. - The lawsuit claims that Klarna's offering documents were materially false and omitted critical information about the company's risk profile related to its buy now, pay later loans [3]. Group 2: Financial Performance and Stock Impact - Following the IPO, Klarna reported a net loss of $95 million on November 18, 2025, and increased provisions for loan losses to $235 million, exceeding analyst estimates of $215.8 million [4]. - Provisions for loan losses represented 0.72% of gross merchandise volume, up from 0.44% the previous year [4]. - By the time the class action lawsuit commenced, Klarna's stock price had fallen to as low as $31.31 per share, significantly below the IPO price of $40 [4]. Group 3: Legal Representation and Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Klarna securities during the IPO to seek lead plaintiff status in the class action lawsuit [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years [6].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and the adequacy of reserves, leading to significant stock price declines following revelations of financial discrepancies [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Postiwala v. Ardent Health, Inc., and it involves purchasers of Ardent Health securities from July 18, 2024, to November 12, 2025, with a deadline of March 9, 2026, for seeking lead plaintiff status [1]. - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable and misrepresented its financial position [3]. Group 2: Allegations Against Ardent Health - Allegations include that Ardent Health's accounts receivable framework allowed for inflated reporting by utilizing a 180-day cliff for reserving uncollectible accounts [3]. - The company reportedly did not maintain sufficient professional malpractice liability insurance and had inadequate reserves to cover increasing social inflationary pressures in medical malpractice cases [3]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in Q3 2025 revenue and a cut to 2025 EBITDA guidance by approximately 9.6%, leading to a nearly 34% drop in stock price [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ardent Health securities during the class period to seek lead plaintiff status, which enables them to represent the interests of the class [5]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Smartsheet Inc. shareholders are encouraged to participate in a class action lawsuit against the company due to alleged violations related to the merger with Blackstone Inc. and Vista Equity Partners, with a deadline for lead plaintiff applications set for February 24, 2026 [1]. Group 1: Class Action Details - The class action lawsuit is titled Kara Eftimoglu v. Mader, No. 25-cv-02530 (W.D. Wash.) and pertains to shareholders who held Smartsheet securities as of October 25, 2024 [1]. - The lawsuit alleges that a misleading Schedule 14A Proxy statement was issued, leading shareholders to approve the merger at an unfair price of $56.50 per share [3]. - The complaint claims that the Proxy failed to disclose critical financial metrics, including the Annual Recurring Revenue (ARR), which was touted in press releases and earnings calls as a key indicator of Smartsheet's financial performance [4]. Group 2: Financial Metrics and Forecasts - Smartsheet's ARR metric was emphasized by management as a significant indicator of future performance, yet it was not included in the Proxy statement [4]. - The Proxy also did not disclose January 2024 forecasts prepared in the ordinary course of business, hindering shareholders' ability to assess the company's financial prospects [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who held Smartsheet securities as of the record date to seek appointment as lead plaintiff in the class action [5]. - A lead plaintiff represents the interests of all class members and can choose a law firm for litigation, with participation in potential recovery not contingent on being the lead plaintiff [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securities class action recoveries for four out of the last five years [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business operations and sales performance during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint claims that Integer overstated its competitive positioning in the market [3]. - It alleges that the company experienced undisclosed deterioration in sales of its electrophysiology devices [3]. - The company mischaracterized the key drivers of its growth, leading to a significant stock price drop of $35.22 per share, a decline exceeding 32% in one day following the announcement of reduced sales guidance [3].